LSG most cost-effective for severe obesity; ESG rivals semaglutide for lower BMI.
Cost-Effectiveness of Endoscopic Bariatric Therapies Compared with Laparoscopic Sleeve Gastrectomy and Semaglutide.
Abstract
LSG is most cost-effective for severe obesity (£10,593/QALY). ESG is cost-effective vs. semaglutide for lower BMI (£7,267/QALY), and semaglutide dominates IGB.